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Malaria contributes significantly to the global disease burden.TheWorldHealthOrganization recommended the use of artemisinin-
based combination therapies (ACTs) for treatment of uncomplicated falciparum malaria a decade ago in response to problems of
drug resistance. This review compared two of the ACTs—Dihydroartemisinin-Piperaquine (DP) and Artemether-Lumefantrine
(AL) to provide evidence which one has the ability to offer superior posttreatment prophylaxis at 28 and 42 days posttreatment.
Four databases (MEDLINE, EMBASE, Cochrane Database and Global Health) were searched on June 2, 2013 and a total of seven
randomized controlled trials conducted in sub-Sahara Africa were included. Results involving 2, 340 participants indicates that
reduction in risk for recurrent new falciparum infections (RNIs) was 79% at day 28 in favour of DP [RR, 0.21; 95% CI: 0.14 to 0.32,
𝑃 < 0.001], and at day 42 was 44% favouring DP [RR, 0.56; 95% CI: 0.34 to 0.90; 𝑃 = 0.02]. No significant difference was seen
in treatment failure rates between the two drugs at days 28 and 42. It is concluded that use of DP offers superior posttreatment
prophylaxis compared to AL in the study areas. Hence DP can help reduce malaria cases in such areas more than AL.
1. Introduction
Malaria has attracted global attention as one of the world’s
leading major diseases due to its high morbidity and mor-
tality. The World Health Organization (WHO) estimated
that about 3.3 billion people are at risk of malaria because
they live in malaria endemic areas [1] and about 300–
500 million malaria cases are reported globally each year
[2]. Malaria is also responsible for almost a million deaths
yearly [2, 3]. The disease is strongly associated with poverty
because it disengages patients from carrying out meaningful
economic activities during attacks and it also consumes huge
expenditure budgets. It is estimated that as high as 40%
of public health expenditure is spent on malaria alone in
endemic countries [4]. Malaria is a febrile disease caused
by parasites of the genus Plasmodium which are transmitted
to susceptible persons through the bite of infected female
Anophelesmosquitoes.
The burden of malaria is greatest in sub-Sahara Africa
where approximately 80% of the global malaria cases as
well as 90% of fatalities occur [1]. Children less than 5
years are the most severely affected accounting for 86% of
the deaths [5]. To this extent, malaria has been recognized
as an impediment to achievement of the United Nation’s
MillenniumDevelopmentGoal (MDG) 4which targets at the
reduction of child mortality [6]. Therefore, without effective
prevention and control of malaria (which is the MDG 6), it
will be difficult to achieve the MDG 4.
In order to minimise the effects of malaria, prompt
clinical diagnosis and effective treatment are needed [7–9]
beside the preventive measures such as use of insecticide
treated nets (ITN) and indoor residual spraying (IRS) with
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Table 1: Plasma half-lives (𝑇
1/2
) of drugs used in some common
ACTs.
Antimalarial drug 𝑇1/2
1 of artemisinin
derivative
𝑇
1/2
of partner
drug
Artemether-
Lumefantrine
(AL)
∼3 hrs 4-5 days
Artesunate-
Amodiaquine
(AMQ)
<1 hr 9–18 days
Dihydroartemisinin-
Piperaquine
(DP)
45min ∼5 weeksSource: [14]
1
𝑇1/2 (half-life): it is the length of time required for half of the concentration
of the ACT drugs in the body of a patient to be eliminated.
insecticides. However, prompt malaria treatment efforts are
being threatened by widespread problem of antimalaria drug
resistance [1, 6, 10]. For instance, Plasmodium falciparum
had developed resistance to chloroquine which was the most
affordable and readily available antimalaria drug in Africa
[10]. As a result, the WHO recommended artemisinin-based
combination therapy (ACT) for treatment of uncomplicated
falciparummalaria [11, 12]. This type of treatment makes use
of combination of an artemisinin derivative with a partner
drug.The artemisinin derivatives are fast acting drugs capable
of rapid clearing of the falciparum parasites during treatment
[12, 13] but have short half-lives which render them almost
unsuitable for use as single therapeutic drugs because of risk
for drug resistance which increases as plasma levels fall [14].
Following the WHO recommendation, most sub-Sahara
African countries have changed their antimalaria drug
policy to the use of the ACTs [15]. Artemether-Lumefantrine
(AL) is one of the ACTs commonly used as first-line
drug for treatment of uncomplicated falciparum malaria
in the sub-Sahara African countries. Another ACT—
Dihydroartemisinin-Piperaquine (DP)—was also recently
recommended by the WHO for use [12]. However, DP is
not widely used in sub-Sahara Africa compared to the use
of AL [1]. The half-lives of the partner drugs in the ACTs
vary across the different ACT drugs available—see Table 1
[14]. The partner drug in AL, Lumefantrine, has a half-life
of ∼5 days while the partner drug in DP, Piperaquine, has
a half-life of ∼5 weeks, the longest of all the ACTS. As a
result, it is being speculated that DP could be the ACT
with greatest posttreatment prophylactic efficacy due to the
longer half-life and sustained plasma levels of Piperaquine
compared to other ACTs such as AL [16]. However, little is
known about the relative extent to which these two ACTs
exert their prophylactic effect after treatment. It is not yet
clear whether the sheer longer half-life of Piperaquine in
DP could translate into a better prophylaxis and to what
extent compared to Lumefantrine in AL. No review had
comprehensively compared these two ACTs head-to-head to
determine their relative prophylactic effectiveness. Earlier
reviews [17, 18] had not explored prophylaxis specifically
in detail.
Olliaro and colleagues found that recurrent new infec-
tions (RNIs) were associated with higher risk for develop-
ment of symptomatic disease (malaria) than recrudescence
parasitaemia [19]. In contrast, other researchers had found
that rather recrudescence parasitaemia carries greater risk for
worse haematological outcome for patients [20]. These two
studies were not conducted on ACTs but the most important
issue at stake here is that both recrudescence and new
infections are associated with various risks to patients; hence,
prevention of their occurrence should be of much concern.
This current review aimed at synthesizing available primary
studies conducted in sub-SaharaAfrica to determinewhether
use of DP reduces incidence of new falciparum infections
(RNIs) and treatment failure more than use of AL within 28
and 42 days after treatment. A clear knowledge in this regard
would offer a better guidance to country antimalaria drug
policies in sub-Sahara Africa. The main review question is,
“Does the use of DP in treating uncomplicated falciparum
malaria reduce the risk for recurrent new falciparum infec-
tions and treatment failure more than AL?”The review tested
the null hypothesis that there is no difference between the two
drugs.
2. Materials and Methods
2.1. Definition of Terms. For purposes of this review, “recur-
rent new falciparum infection” (RNI) is defined as new
infections which patients acquired by day 28 or 42 following
treatment for uncomplicated falciparum malaria using DP
or AL. “total treatment failure” (TTF) refers to recrudes-
cence recorded by day 28 or day 42 (Tables 5 and 6) after
treatment, where recrudescence refers to the “old” or the
original parasites for which the antimalaria treatment was
initiated but could not be cleared by the antimalaria drug
and the disease (symptomatic malaria) has returned. The
new infections must have been differentiated from the “old”
infections in the primary studies by use of polymerase chain
reaction (PCR). Prophylactic effectiveness used in this review
refers to the ability of the ACT drug (DP orAL) to prevent the
occurrence of new falciparum infections within 28 or 42 days
after treatment with either drug (Tables 7 and 8).
2.2. Inclusion and Exclusion Criteria. Studies were included
in the review if they were randomized controlled trial (RCT)
conducted in sub-Sahara Africa and had compared the two
drugs (DP and AL) head-to-head for treatment of uncompli-
cated falciparum monoinfections only. All patients recruited
for the primary studies must have been confirmed through
laboratory investigation to be infected with P. falciparum
only and must not have shown signs of severe malaria or be
suffering from co-febrile infection at the time of enrolment.
The trial must be conducted according to theWHOprotocols
for antimalaria drug efficacy study. Studies which included
pregnant women were excluded.
2.3. Database Search Strategy. An electronic search to locate
relevant published studies was conducted in four main
databases, namely, EMBASE, MEDLINE, Cochrane Library,
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Table 2: The electronic search strategy.
#1. Malaria [MeSH]-search “exploded” and all subheadings included
#2. Malaria [free text]
#3. Uncomplicated malaria [free text]
#4. Uncomplicated falciparum malaria [free text]
#5. Simple malaria [free text]
#6. #1 OR #2 OR #3 OR #4 OR #5
#7. Dihydroartemisinin plus Piperaquine [MeSH]-search “exploded” and all subheadings included
#8. Dihydroartemisinin plus Piperaquine [free text]
#9. Dihydroartemisinin-Piperaquine [free text]
#10. Dihydroartemisinin [free text]
#11. Arteether [MeSH]-search “exploded” and all subheadings included
#12. Dihydroartemisinin [MeSH]-search “exploded” and all subheadings included
#13. #7 OR #8 OR #9 OR #10 OR #11 OR #12
#14. Artemether plus Lumefantrine [MeSH]-search “exploded” and all subheadings included
#15. Artemether plus Lumefantrine [free text]
#16. Artemether-Lumefantrine [free text]
#17. Artemether Lumefantrine [free text]
#18. Arteether [MeSH]-search “exploded” and all subheadings included
#19. Coartem [free text]
#20. Riamet [free text]
#21. Coarteme [free text]
#22. Co-artemether [free text]
#23. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR # 21 OR 22
#24. #6 AND #13 AND #23
#25. Limit #24 to human and English language
and Global Health, using the search strategy presented in
Table 2. The final database search for the review was con-
ducted in the selected databases on June 2, 2013, as follows:
EMBASE: from 1980 to 2013 week 22; MEDLINE: from
1946 to May 2013 week 4; Global Health: from 1973 to 2013
week 21.
The main terms in the review question were structured
into the PICO (population, intervention, comparison, and
outcome) format and all corresponding synonyms identified.
All main terms in the review question were searched under
medical subject heading (MeSH terms) and also as free texts.
Each MeSH term search was “exploded” and all subheadings
were included. All other terms (synonyms of the main terms)
were searched as free texts. Search results of terms under
the same category were brought together using the Boolean
operator “OR,” while the Boolean operator “AND” was used
finally (once) to bring all “OR” results together. The final
search result after use of the Boolean operator “AND” was
limited to studies conducted on humans and have been
published in English language—see Table 3. Only terms in
the population, intervention, and comparison categorieswere
used during the search because the reviewers were of the
view that further inclusion of terms in the outcome category
in the search might lead to exclusion of some important
studies. All search results were reviewed by WA and cross-
checked by EP and studies that met the inclusion criteria
selected. Due to the limited time available for the review,
no trial author was contacted for further clarification on
the trials and, as a result, articles with instances of unclear
or missing data were excluded.The preferred reporting items
for systematic reviews and meta-analysis (PRISMA) flow
diagram [21] has been used to summarize study selection
process—see Figure 1.
2.4. Assessment of Quality (Risk of Bias) of Included Stud-
ies. The methodological quality of the selected studies was
assessed using the “Cochrane Collaboration’s tool for assess-
ing risk of bias” [22]. The assessment tool covers six domains
for assessing internal validity of studies. These domains
include sequence generation, allocation concealment, blind-
ing of participants or outcome assessors, incomplete outcome
data, selective outcome reporting, and other sources of
bias [22].
2.5. Data Extraction and Analysis. All data were extracted
as binary data in the form of number of participants who
experienced the event of interest and total number of par-
ticipants in each study group. The outcomes of interest
included recurrent new falciparum infections (RNIs) and
total treatment failure (TTF) reported by day 28 and 42. Data
on new infection and treatment failure were extracted using
the differentiated PCR results recorded in the studies. Data
extraction was done by author WA and figures were cross-
checked by author EP for accuracy. Instances of disagreement
on the accuracy of the extracted figures were resolved by
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Global Health:
152 obtained
Embase:
555 obtained
Medline:
139 obtained
Cochrane library:
827 obtained
Total of 1,673
papers obtained
1,631 papers 
removed on the basis 
of irrelevance
42 papers
selected for abstract 
review
31 papers removed on the basis
of duplications and irrelevant
study objective and aim
11 papers
selected for full text 
reading and scrutiny 
4 papers excluded for 
various reasons    
(see Table 4 for the 
various reasons for 
exclusion)7 papers included
in the narrative review 
and the meta-analysis
Figure 1: The preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram showing database search results
and selection stages.
extensive discussions and explanations and then agreement
is finally reached on which figure is accurate.
Data analysis was done using the Comprehensive Meta-
Analysis programme (CMAP) version 2.0 [23]. Effect sizes
were calculated in risk ratio (RR) at 95% confidence inter-
val (CI). Results of DP group relative to AL group were
regarded as statistically significant if the 95% CI did not
include number of no effect, which is 1. Absolute relative
difference (ARD) and number needed to treat (NNT) were
calculated [24].The grading of recommendations assessment,
development, and evaluation (GRADE) system (Table 9) was
used to assess level of evidence quality [25, 26]. The meta-
analyses were done in the random effects model. This model
operates on the premise that each trial included in the
analysis has estimated an effect size peculiar to its study
population and that any difference in effect estimation across
the studies is due to both random error and heterogeneity
[27]. Statistical heterogeneity was assessed to determine 𝐼-
squared (𝐼2), the𝑄-value, and the accompanying𝑃 values [27,
28]. The 𝐼2 values were interpreted as follows: 𝐼2 values less
than 50% were regarded as low, values ≥ 50% were regarded
as moderate, and an 𝐼2 above 75% was interpreted as high
or substantial heterogeneity [24, 28]. The level of statistical
significance for heterogeneity 𝑃 value was set at 10% [28].
3. Search Result
A total of 1,673 records were retrieved from all the database
searches combined and 1,631 records (97.5%) were excluded
initially because they have irrelevant study titles. Abstract of
the remaining 42 publications (2.5%)were read, afterwhich 11
(26.2%) were further selected and subjected to thorough full
text reading and scrutiny. Seven studies [29–35] were finally
selected for inclusion in the review.
The remaining four [15, 36–38] were excluded for various
reasons (see Table 3 for reasons for exclusion). Table 4 con-
tains general description of selected studies.
3.1. Risk of Bias Assessment Results of Selected Studies
3.1.1. Adequate Sequence Generation and Allocation Conceal-
ment. Sequence generation was done adequately in all the
studies and was judged to pose a low risk of bias. Four of the
trials used computer generated random list done by an off-site
Malaria Research and Treatment 5
Table 3: Table of excluded studies and reasons for exclusion.
Study name Design, country Sample size Reasons for exclusion
Nambozi et al., 2011 [36] RCT, Zambia 304
The study has been reported as part of the larger
multicentric study of Bassat et al., 2009, already
included in the review
Arinaitwe et al., 2009 [15] RCT, Uganda 351
Some of the study participants were infected with other
species of Plasmodium. The reviewer was only
interested in primary studies in which only P.
falciparum infections were treated.
Verret et al., 2011 [37] RCT, Uganda 292
This study is a subanalysis of the main study of
Arinaitwe et al., 2009, which was also excluded from
the review with reasons as the above.
Katrak et al., 2009 [38] RCT, Uganda 246
There was no data on treatment failure; only adverse
events were presented. The main aim of the study was
to investigate safety of study drugs among HIV-infected
and HIV-uninfected children, which is not relevant for
this review.
investigator. One trial [29] reported use of block randomisa-
tion while the remaining two [32, 34] used stratified random
lists generated by off-site investigators (Figure 2). Five trials
[29, 30, 32, 33, 35] used adequate allocation concealment
methods and were judged to be at low risk for selection
bias because the researchers used sequentially numbered,
sealed opaque envelops to obscure treatment group before
allocation. The concealment process was judged to pose an
unclear risk of bias in only two of the studies [31, 34] for lack
of clear information.
3.1.2. Blinding. Blinding was judged to be adequate (low risk
of bias) in six studies [30–35] because all laboratory personnel
and trial investigators involved in assessing outcome mea-
sures were blinded to the treatment allocation of the study
participants. This was deemed to pose low risk of bias to
parasitological outcome measures for treatment failure and
rate of new infections. One study [29] did not report on
blinding and was judged to pose high risk of measurement
and performance bias.There was no blinding for participants
and nurses in four studies and this was considered to pose
rather high risk of bias to the outcome measures of adverse
clinical events (side effects of the drugs) which were not the
focus of this review.
3.1.3. Inclusion of All Participants in the Final Analysis. All the
trials selected addressed incomplete outcome data and were
rated to be of low risk for attrition bias. More than 90% of
randomised participants were included in final analysis in all
the trials and this was deemed adequate.The highest attrition
rate was 7.6%.
3.1.4. Other Sources of Bias. The reviewer identified no other
important source of bias.
4. Findings
4.1. Total Treatment Failure (TTF) at Day 28. Result on total
treatment failure (TTF) due to recrudescence was obtained
from six studies and involved a total of 3,172 patients. Of
this, 1,861 participants received DP, out of which 107 (5.7%)
experienced treatment failure at day 28. On the other hand,
1,311 received AL, of which 80 (6.1%) experienced treatment
failure. The pooled RR yielded 0.453, 95% CI: [0.203 to 1.012,
P = 0.05]. This implies that there was an average of 55%
reduction in risk for TTF at day 28 in favour of DP treatment;
largest plausible reduction possible was 80%; however, the
upper boundary of the 95% CI includes the number of no
effect (1) and a risk for harm of 1.2%.
Extent of heterogeneity was 47% (𝐼2 = 47, 𝑃 = 0.09,
𝑄-value = 9.5, df = 5) and this level of heterogeneity was
considered to be low [28]—see Figure 3.The pooledARDwas
0.016, 95% CI [0.030–0.002, 𝑃 = 0.02], which means that for
every 63 patients treatedwithDP, one case of treatment failure
was prevented, which would have occurred if such patients
had received AL treatment.
4.2. Total Treatment Failure (TTF) at Day 42. Data on TTF
at day 42 was extracted from four studies involving 2, 662
participants, out of which treatment failure was reported
in 274 participants representing 10.3%. A total of 1,598
participants were those treated with DP and 161 of them
(10.1%) experienced treatment failure. Those who received
AL treatment were 1,064 participants out of which 113(10.6%)
experienced failure, an indication thatDPwas associatedwith
a marginal reduction in treatment failure compared to AL.
The pooled estimate for the RR was 0.560 with 95% CI of
[0.275 to 1.140, 𝑃 = 0.1]. This implies that there was an
average reduction in risk of treatment failure of 44% in favour
of DP treatment compared to AL, with the highest plausible
reduction in risk of up to 73%. However, the upper boundary
of the 95% CI includes number of no effect (1) and includes
14% harm of failure. Test for heterogeneity in random effect
model shows high statistical heterogeneity of 71% across the
studies (𝑄 =10, df (𝑄) = 3, 𝐼2 = 71%, 𝑃 = 0.02)—see Figure 4.
4.3. Recurrent New Infections (RNIs) Reported at Day 28.
Results from four studies involving a total of 2,340 patients
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Table 5: Findings on total treatment failure (TTF), PCR-corrected by day 28.
Study name Study groups withnumber of failures Risk (𝑅)
Risk ratio (RR)
(95% CI) 𝑃 value Interpretation for RR values
Bassat et al.,
2009 [32]
DP (𝑁/𝑁): 100/1038
AL (𝑛/𝑁): 51/510
0.096
0.010
0.963
(0.699–1.327) 0.819
This means there is 3.7% reduction in risk of
failure in favour of DP treatment but the result is
not statistically significant. The highest possible
reduction in risk was 30.1%, favouring DP.
Yavo et al.,
2011 [33]
DP (𝑛/𝑁): 1/191
AL (𝑛/𝑁): 2/183
0.005
0.011
0.479
(0.044–5.238) 0.546
Treatment with DP had contributed to a point
estimate of 52.1% reduction in treatment failure,
with highest possible reduction of 95.6% but the
result is not statistically significant.
Kamya et al.,
2007 [30]
DP (𝑛/𝑁): 4/211
AL (𝑛/𝑁): 18/210
0.019
0.087
0.220
(0.076–0.639) 0.005
This result shows that DP treatment was
associated with a point estimate reduction of 78%
in treatment failure, with lowest and highest of the
estimates being 36.1% and 92.4%, respectively, and
is statistically significant.
Sawa et al.,
2013 [34]
DP (𝑛/𝑁): 0/137
AL (𝑛/𝑁): 2/147
0.000
0.014
0.214
(0.010–4.428) 0.319
DP treatment had contributed to 78.6% reduction
in treatment failure but it is not statistically
significant. The largest plausible reduction would
be 99%.
Adam et al.,
2010 [29]
DP (𝑛/𝑁): 0/75
AL (𝑛/𝑁): 1/74
0.000
0.014
0.329
(0.014–7.947) 0.494
Result shows a statistically insignificant difference
between DP and AL treatment in preventing
treatment failure but indicates that there was a
67.1% risk of failure reduction in favour of DP
treatment (1 > RR,
1 − RR = 1 − 0.329 = 0.671 × 100 = 67.1%).
Yeka et al.,
2008 [35]
DP (𝑛/𝑁): 2/211
AL (𝑛/𝑁): 6/190
0.009
0.032
0.300
(0.061–1.469) 0.138
Result is not significant statistically but there was
a reduction in failure in favour of DP treatment of
70%. The highest reduction possible was 93.9% in
favour of DP treatment of falciparummalaria.
Table 6: Findings on total treatment failure (TTF), PCR-corrected by day 42.
Study name Study groups withnumber of failures Risk (𝑅)
Risk ratio (RR)
(95% CI) 𝑃 value Interpretation of RR values
Bassat et al.,
2009 [32]
DP (𝑁/𝑁): 143/1038
AL (𝑛/𝑁): 68/510
0.138
0.133
1.033
(0.790–1.352) 0.811
There was a marginal increase in treatment failure
of 3.3% associated with DP treatment but it is not
statistically significant.
Kamya et al.,
2007 [30]
DP (𝑛/𝑁): 13/211
AL (𝑛/𝑁): 28/210
0.062
0.133
0.452
(0.245–0.867) 0.016
This result shows that DP treatment was
associated with a point estimate reduction of
54.8% in treatment failure; with lowest and
highest of the estimates being 13.3% and 75.5%,
respectively, and it is statistically significant.
Sawa et al.,
2013 [34]
DP (𝑛/𝑁): 0/134
AL (𝑛/𝑁): 4/145
0.000
0.028
0.120
(0.007–2.211) 0.154
DP treatment had contributed to 88% reduction
in treatment failure but it is not statistically
significant. The largest plausible reduction was
99.3%.
Yeka et al.,
2008 [35]
DP (𝑛/𝑁): 5/215
AL (𝑛/𝑁): 13/199
0.023
0.065
0.356
(0.129–0.981) 0.045
This result is statistically significant. There was a
reduction in failure in favour of DP treatment of
64.4%. The highest possible reduction was 87%
and the lowest was 2% in favour of DP treatment
of falciparum malaria.
showed that 104 of the patients (representing 4.4%) acquired
new falciparum infectionswithin the 28 day period after treat-
ment. Out of the total number, 1,433 participants received
DP, of which 28 patients representing 2% had new infections.
In the AL group, 907 patients received the treatment and
76 (8%) acquired new infections—an indication that rate of
new falciparum infection was higher among those treated
with AL than those treated with DP. Pooled RR was 0.207,
95% CI [0.136 to 0.315, 𝑃 < 0.001]. This indicates that
risk associated with a patient getting new infections at day
28 was significantly reduced averagely by 79% in favour
of DP treatment. The lowest plausible reduction was 69%
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Table 7: Findings on new falciparum infections detected by day 28.
Study name
Study groups with
number of new
infections
Risk (𝑅) Risk ratio (RR)(95% CI) 𝑃 value Interpretation for the RR values
Sawa et al.,
2013 [34]
DP (𝑛/𝑁): 0/137
AL (𝑛/𝑁): 8/147
0.00
0.054
0.063
(0.004–1.083) 0.057
There has been 37% reduction in new infections
associated with DP treatment but reduction is not
statistically significant.
Yavo et al.,
2011 [33]
DP (𝑛/𝑁): 1/191
AL (𝑛/𝑁): 3/183
0.005
0.016
0.319
(0.034–3.042) 0.321
There was a 68% reduction in new infections in
favour of DP treatment but result not statistically
significant.
Bassat et al.,
2009 [32]
DP (𝑛/𝑁): 27/1038
AL (𝑛/𝑁): 64/510
0.026
0.125
0.207
(0.134–0.321) <0.001
This result shows 79% reduction in incidence of
new falciparum infections in favour of DP
treatment and the reduction is statistically
significant. The lowest plausible reduction is
67.9% while the highest is 86.6% as defined by the
95% CI of the RR.
Mens et al.,
2008 [31]
DP (𝑛/𝑁): 0/67
AL (𝑛/𝑁): 1/67
0.000
0.015
0.333
(0.014–8.039) 0.499
DP treatment was associated with a 66.7%
reduction in risk for a patient to acquire new
infections compared to AL. The reduction is not
statistically significant.
Table 8: Total new falciparum infections detected by day 42.
Study name
Study groups with
number of new
infections
Risk (𝑅) Risk ratio (RR)(95% CI) 𝑃 value Interpretation for the RR values
Sawa et al.,
2013 [34]
DP (𝑛/𝑁): 3/134
AL (𝑛/𝑁): 23/145
0.022
0.159
0.141
(0.043–0.459) 0.001
There has been 85.9% reduction in new infection
associated with DP treatment. Highest plausible
reduction is 95% while lowest is 54% defined by the
95% CI. The reduction is statistically significant.
Yeka et al.,
2008 [35]
DP (𝑛/𝑁): 16/215
AL (𝑛/𝑁): 30/199
0.074
0.151
0.494
(0.278–0.878) 0.016
There was 50.6% reduction in risk to acquire new
falciparum infection in favour of DP treatment and the
reduction is statistically significant.
Bassat et al.,
2009 [32]
DP (𝑛/𝑁): 122/1038
AL (𝑛/𝑁): 105/510
0.118
0.206
0.571
(0.450–0.725) <0.001
This result shows 42.9% reduction in risk of getting new
infections with falciparum and the reduction was in
favour of DP and is statistically significant. The lowest
plausible reduction is 27.5% while the highest is 55% as
defined by the 95% CI of the RR.
Kamya et al.,
2007 [30]
DP (𝑛/𝑁): 77/211
AL (𝑛/𝑁): 79/210
0.365
0.376
0.970
(0.756–1.244) 0.811
DP treatment was associated with only 3% risk
reduction for new infection and the reduction is
statistically insignificant.
and highest was 86%; the difference was statistically signifi-
cant (𝑃 < 0.001)—Figure 5.
4.4. Recurrent New Infections (RNIs) Detected at Day 42.
Results extracted from four studies involving a total of
2,662 patients indicated that 455 patients representing 17%
experienced new infections with falciparum parasites. Those
treated with DP were 1,598, out of which 218 (14%) acquired
new falciparum infections. On the other hand, a total of 1,064
received AL, of which 237 (22%) experienced new infections.
The pooled RRwas 0.557, 95%CI [0.342 to 0.908].Thismeans
that the risk of a patient acquiring new falciparum infection
at 42 day following treatment was averagely reduced by 44%
in favour of DP compared to AL—see Figure 6. The 95% CI
was 0.342 to 0.908, suggesting that the actual effect could be
anywhere between 9 and 66%; the difference was statistically
significant, 𝑃 = 0.02. There was a substantial heterogeneity
(extent was 83%) associated with this result (𝐼2 = 83,𝑄-value
= 18, df = 3, 𝑃 < 0.001).
5. Discussion
This review compared two ACTs—Dihydroartemisinin-
Piperaquine (DP) and Artemether-Lumefantrine (AL)—to
determine which has the greatest effect in reducing recurrent
new falciparum infections (RNIs) and treatment failure. The
null hypothesis which was tested was that there is no differ-
ence between the two drugs in reducing risk of treatment
failure and recurrent new falciparum infections at days 28
and 42. However, the overall evidence gathered suggests that
patients who were treated with DP experienced less total
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Domains used for assessing risk of bias 
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3 
[3
4]
(1) Adequate sequence generation (checking for possible selection 
bias)
(2) Allocation concealment (checking for possible selection bias) 
(3) Blinding (assessing for possible performance/measurement 
bias)
(4) Incomplete outcome data addressed (assessing for possible 
attrition bias)
(5) Free of selective reporting (checking for possible reporting bias) 
(6) Free of other biases (checking for other biases)
Notes:
Based on the authors’ judgement,  
information about the domain to warrant a “yes” or “no” judgement by the reviewer);
this colour = “yes” judgement which implies low risk of bias (meaning method for addressing domain was adequately performed);
this colour stands for “unclear” judgement which means reviewer is uncertain about risk of bias (there was insufficient
this colour means a “no” judgement implying there is high risk of bias (the method for addressing the domain was not performed).
Figure 2: Result of risk of bias assessment for included studies.
Study name Statistics for each study Risk ratio and 95% CI
Risk Lower Upper Relative Relative 
ratio limit limit weight weight
Adam et al., 2010 0.329 0.014 7.947 5.53
Sawa et al., 2013 0.214 0.010 4.428 6.03
Yavo et al., 2011 0.479 0.044 5.238 8.90
Yeka et al., 2008 0.300 0.061 1.469 15.92
Kamya et al., 2007 0.220 0.076 0.639 24.17
Bassat et al., 2009 0.963 0.699 1.327 39.45
0.453 0.203 1.012
0.01 0.1 1 10 100
Favours DP Favours AL
Heterogeneity: Q-value = 9.5, df = 5 (P = 0.09), I2 = 48; test of null (2-tail): Z-value = −1.93 (P = 0.05)
Z-value
−0.684
−0.997
−0.603
−1.485
−2.783
−0.228
−1.932
Figure 3: Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of total treatment failure (PCR-
corrected) at day 28.
treatment failure (TTF) and less recurrent new falciparum
infections (RNIs) than those who received AL.
Majority of studies included in this review were con-
ducted in East Africa and only few were carried out in
West Africa and therefore findings and conclusion are more
applicable to countries in the East Africa region.The evidence
synthesized indicates that both DP and AL are effective in
preventing treatment failure at days 28 and 42 after treatment.
However, DP reduced treatment failure higher than AL at
28 and 42 days but the difference in magnitude of failure
reduction between the two drugs is clinically marginal and
not statistically significant. This finding concurs with that of
earlier review conducted on studies done in Asia, America,
and Africa [18], in which DP was found to be associated with
an appreciable efficacy of cure rate compared to non-ACTand
other ACT drugs.The average percentage of risk reduction in
favour of DP compared to AL in this review decreased from
55% at day 28 to 44% at day 42. This confirms the assertion
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Study name Statistics for each study Risk ratio and 95% CI
Risk Lower Upper Relative Relative 
ratio limit limit weight weight
Sawa et al., 2013 0.120 0.007 2.211 5.22
Yeka et al., 2008 0.356 0.129 0.981 22.80
Kamya et al., 2007 0.462 0.246 0.867 31.88
Bassat et al., 2009 1.033 0.790 1.352 40.09
0.560 0.275 1.140
0.01 0.1 1 10 100
Favours DP Favours AL
Heterogeneity: Q-value = 10, df = 3 (P = 0.02), I2 = 71; test of null (2-tail): Z-value = −1.59 (P = 0.1).
Z-value
−1.426
−1.998
−2.404
0.239
−1.598
Figure 4: Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of total treatment failure (PCR-
corrected) at day 42.
Study name Statistics for each study Risk ratio and 95% CI
Risk Lower Upper Relative Relative 
ratio limit limit weight weight
Mens et al., 2008 0.333 0.014 8.039 1.75
Sawa et al., 2013 0.063 0.004 1.083 2.19
Yavo et al., 2011 0.319 0.034 3.042 3.48
Bassat et al., 2009 0.207 0.134 0.321 92.58
0.207 0.136 0.315
0.01 0.1 1 10 100
Favours DP Favours AL
−0.677
−1.905
−0.992
−7.056
−7.346
Heterogeneity: Q-value = 0.9, df = 3 (P = 0.8), I2 = 0.00; test of null (2-tail): Z-value = −7.34 (P = 0.001).
Z-value
Figure 5:Analysis forDihydroartemisinin-Piperaquine versusArtemether-Lumefantrine for outcomeof recurrent new𝑓𝑎𝑙𝑐𝑖𝑝𝑎𝑟𝑢𝑚 infection
at day 28.
by Yeka and colleagues that as length of followup increases,
difference between DP and AL in their ability to prevent
treatment failure in high endemic areas becomes insignificant
[35]. This observation is attributed to the overwhelming rate
of new infections in such areas which may have outweighed
the efficacy of Piperaquine coupled with the decreasing
concentration of Piperaquine in the blood stream over time.
It has been speculated that DP could offer a greater
posttreatment prophylaxis (PTP) than other ACTs due to its
longer half-life by which it could exert longer efficacy against
newly infecting parasites and reduce risk for development
of both clinical malaria and resistance parasite strains [14].
However, the extent to which DP could offer prophylaxis
(PTP) by preventing clinical malaria due to new infections
has not been clearly specified compared to other ACTs such
as AL.
Result on prevention of recurrent new falciparum infec-
tions (RNIs) in this review demonstrates that DP offered
greater and significant PTP for patients against RNI than AL.
Average percentage reduction in risk for RNI was up to 79%
at day 28 in favour of DP and up to 44% at day 42 in favour
of DP. There is, however, substantially significant statistical
heterogeneity (extent was 83%) associated with pooled result
on RNI at day 42 in this review. The possible source of
this heterogeneity is attributed to the variability in malaria
infection transmission rate of the various study sites; some of
the studies were conducted in settings where rate of malaria
transmission intensity was very high while other studies were
conducted in areas of relatively low malaria transmission
intensity. Thus, study settings with very high transmission
intensity are likely to be associated with higher rates of
Anopheles mosquito bites which will result in recurrent
new infections more than settings with low transmission
intensities. Even though participants were provided with
insecticide treated nets, it cannot be ascertained whether
patients actually slept in the nets to prevent mosquito bites
after treatment and this could also affect the proportion of
patient who experienced recurrent new infections.
The superiority of DP in offering this higher level of
posttreatment prophylaxis (PTP) is attributable to the longer
half-life of Piperaquine (which is ∼5 weeks) compared to the
shorter half-life (of about 4 to 5 days) of Lumefantrine in AL
[14]. The higher PTP of DP will be of significant importance
for areas of higher malaria transmission intensities more
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Study name Statistics for each study Risk ratio and 95% CI
Risk Lower Upper Relative Relative 
ratio limit limit weight weight
Sawa et al., 2013 0.141 0.043 0.459 11.52
Yeka et al., 2008 0.494 0.278 0.878 23.67
Kamya et al., 2007 0.970 0.756 1.244 32.29
Bassat et al., 2009 0.571 0.450 0.725 32.52
0.557 0.342 0.908
0.01 0.1 1 10 100
Favours DP Favours AL
−3.252
−2.405
−0.239
−4.609
−2.348
Heterogeneity: Q-value = 18, df = 3 (P < 0.001) , I2 = 83; test of null (2-tail): Z-value = −2.35 (P = 0.02).
Z-value
Figure 6: Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of recurrent new 𝑓𝑎𝑙𝑐𝑖𝑝𝑎𝑟𝑢𝑚
infection at day 42.
than for areas of low transmission intensities which are
associated with lower frequency of acquiring malaria due to
new infections. However, in spite of the benefit of higher PTP
of DP it must also be pointed out that the longer half-life of
Piperaquine is likely to pose high risk for faster development
of drug resistant strains of the falciparum parasites to DP
[14]. This is thought to be possible because the new infecting
parasites will be exposed to subtherapeutic (low) concen-
trations of Piperaquine over time. This low concentration
will not be able to eliminate the parasites completely and
will provide an opportunity for development of resistant
strains. Therefore, any attempt to promote more utilisation
of DP for the benefit associated with its higher PTP must be
weighed against the possible risk for development of resistant
strains because of potential public health dangers associated
with drug resistant parasites. Notwithstanding, the risk for
development of drug resistant parasites could be minimized
if more than one ACT drug is used as a first-line drug for
treatment of uncomplicated malaria in a particular area [15].
The use of more than one drug as a first-line ACT may
prevent the possibility of the parasites becoming adjusted to
one overused-first-line ACT. There is, therefore, the need for
encouraging the use of multiple first-line drugs and constant
monitoring of efficacy of the ACT drugs to determine
development of resistant strains at early stages.
5.1. Clinical and Policy Implications of Findings. Using the
GRADE criteria for rating evidence quality [26], the quality
of evidence obtained regarding superiority of DP over AL
in preventing TTF at day 28 was rated moderate quality
while that of day 42 was rated low quality. Evidence obtained
on prophylactic superiority of DP over AL in preventing
RNI at day 28 was rated high quality while that of day 42
was rated moderate quality. High quality GRADE evidence
rating means that the authors are very confident that the
true effect lies close to the average estimated while moderate
quality rating means that authors’ confidence in the estimate
is moderate which means that the true effect size is likely to
be close to the average estimate, but there is also likelihood
that there could be substantial difference [26].
It is worth indicating that treatment failure (TTF) and
recurrent new infections (RNIs) are of great importance
and concern to patients due to the negative socioeconomic
impact of clinical malaria on patients. Malaria imposes high
economic burden on patients by preventing them from
working when the disease attacks them and this slows work
force productivity. Malaria is highly prevalent in sub-Sahara
Africa and it is undeniable that patients acquiring frequent
recurrent new infections contribute to the high number of
cases. Therefore, preventing RNIs means that an appreciable
proportion of the population would remain healthier for
productive economic activities and this could help reduce the
malaria expenditure burden on the healthcare system and
on the continent as well as on donor agencies. Considering
these reasons above and level of relative reduction in risk for
TTF and RNI in favour of DP together with the quality of
the evidence obtained, these findings are considered to be of
clinical and country malaria policy significance.
5.2. Strengths of the Review. All studies included in the
review were RCTs which is appropriate for answering clinical
intervention questions. The methodological quality of the
selected studies was generally high and had been rated to pose
low risk of bias. Meta-analysis was done in random effects
model to integrate extracted data for better interpretation
and all these are considered as strengths of the review.
Data extracted from the various studies were done by AW
and cross-checked by EP to ensure accuracy and prevent
individual bias.
5.3. Limitations of the Review. There was no attempt to locate
studies in the grey literature and other sources apart from
those indexed in the four databases searched. Search results
were limited to studies published in English language alone
and therefore excluded other equally valuable articles which
might have been published in other languages such as French.
All of these carry a potential risk of selection bias which could
undermine the completeness of the review data and weaken
findings and conclusion.There are variations associated with
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the studies. Firstly the studies were conducted in different
sites that have different malaria transmission intensities.
Studies also recruited participants with different age groups.
Also, majority of the included studies were conducted in
countries in East Africa which weakens generalisation of
findings to other parts of sub-SaharaAfrica; hence this review
result and conclusion are most valid for countries in East
Africa. There is high statistical heterogeneity associated with
some estimates; hence each pooled effect estimate must be
seen as an average representing different estimates which are
peculiar to each study population, bearing in mind, however,
that effect directionswere similar and, inmost cases, favoured
DP (see forest plots in Figures 3–6).
6. Conclusion
This systematic review compared Dihydroartemisinin-
Piperaquine (DP) and Artemether-Lumefantrine (AL) and
aimed at identifying which one has greater ability to reduce
total treatment failure (TTF) and incidence of recurrent
new falciparum infections (RNIs) in high transmission areas
in sub-Sahara Africa. The results showed that participants
treated with DP compared to AL experienced lesser risk for
TTF at days 28 and 42.
On the other hand, DP offers a significant posttreat-
ment prophylaxis against recurrent new falciparum infections
superior to that of AL. The average percentage reduction
in risk for the incidence of RNI was up to 79% at day
28 in favour of DP [RR, 0.21; 95% CI: 0.14 to 0.32, 𝑃 <
0.001] and 44% in favour of DP at day 42 [RR, 0.56; 95%
CI: 0.34 to 0.90; 𝑃 = 0.02]. It is, therefore, concluded
that treatment of uncomplicated falciparum malaria using
Dihydroartemisinin-Piperaquine (DP) in high transmission
areas in sub-Sahara Africa (especially East Africa) could
result in an average reduction in risk for recurrent new
falciparum infections of up to 79% and 44% within 28 and
42 days, respectively, compared to Artemether-Lumefantrine
(AL). And this implies that use of DP can help reduce burden
ofmalaria in such areasmore thanAL.However, bothDP and
AL have similar effectiveness in preventing treatment failure
though DP has marginal benefit over AL.
7. Recommendation
It is recommended that the antimalaria drug policy in
countries especially in East Africa should be streamlined
to include use of Dihydroartemisinin-Piperaquine along-
side Artemether-Lumefantrine and other ACTs in countries
where it is found to be effective but this must be done bearing
in mind the potential risk for development of resistant
falciparum strains. More studies should be conducted in
other parts of the sub-Sahara Africa such as West Africa to
determine stronger evidence which will be more applicable
to countries in that area.
It has been identified that the current study protocol by
the WHO regarding antimalaria drug efficacy research does
not incorporate specific outcome measure on recurrent new
infections. It is, therefore, recommended that measurement
of rate of recurrent new infections should be incorporated
into future guidelines, and future trial investigators should
make direct assessment on it.
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